Christoph W. Zapf
Bristol-Myers Squibb (Germany)(DE)Nurix (United States)(US)
Publications by Year
Research Areas
Protein Degradation and Inhibitors, Chemical Synthesis and Analysis, Click Chemistry and Applications, CAR-T cell therapy research, Computational Drug Discovery Methods
Most-Cited Works
- → Diprotected Triflylguanidines: A New Class of Guanidinylation Reagents(1998)213 cited
- → Chemoselective Electrosynthesis Using Rapid Alternating Polarity(2021)171 cited
- → Discovery of Clinical Candidate 1-{[(2 S ,3 S ,4 S )-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a Potent, Selective Inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4), by Fragment-Based Drug Design(2017)139 cited
- → A Diels–Alder Macrocyclization Enables an Efficient Asymmetric Synthesis of the Antibacterial Natural Product Abyssomicin C(2005)110 cited
- → Covalent Inhibitors of Interleukin-2 Inducible T Cell Kinase (Itk) with Nanomolar Potency in a Whole-Blood Assay(2012)78 cited
- → New reagents, reactions, and peptidomimetics for drug design(2001)49 cited
- → Discovery of a stable macrocyclic o-aminobenzamide Hsp90 inhibitor which significantly decreases tumor volume in a mouse xenograft model(2011)35 cited
- → Solid-Phase Synthesis of Pyridones and Pyridopyrazines as Peptidomimetic Scaffolds(1999)33 cited
- → Discovery of 3-Cyano- N -(3-(1-isobutyrylpiperidin-4-yl)-1-methyl-4-(trifluoromethyl)-1 H -pyrrolo[2,3- b ]pyridin-5-yl)benzamide: A Potent, Selective, and Orally Bioavailable Retinoic Acid Receptor-Related Orphan Receptor C2 Inverse Agonist(2018)32 cited